Physician profile
Erika Rumble
NPI 1437695715
$2,315.21
in general payments reported to CMS, 2019-2025
23 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 98% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $172 · 2024: $420 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.10 |
| Education | $245.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $499.21 | 2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $261.50 | 2024-2025 | Trodelvy |
| Lilly USA, LLC | $209.14 | 2025 | Verzenio, Retevmo, Jaypirca |
| Merck Sharp & Dohme LLC | $147.38 | 2024-2025 | Keytruda, Lynparza |
| Mayne Pharma Commercial LLC | $145.72 | 2023-2024 | |
| Genentech, INC. | $131.20 | 2025 | Itovebi |
| Abbvie INC. | $120.72 | 2022-2025 | |
| Stemline Therapeutics INC. | $114.45 | 2025 | Orserdu, Elzonris |
| Eisai INC. | $102.20 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $99.50 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $96.81 | 2024-2025 | |
| Therapeuticsmd, INC. | $66.29 | 2022 | |
| Genentech USA, INC. | $65.01 | 2024-2025 | Phesgo, Itovebi |
| Organon LLC | $59.28 | 2022-2024 | Nexplanon |
| Astellas Pharma US INC | $43.40 | 2023-2024 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucent Medical | $32.47 | 2025 | |
| Tersera Therapeutics LLC | $22.71 | 2025 | Zoladex |
| Myovant Sciences INC. | $18.60 | 2022 | |
| Caris Mpi, INC. | $18.36 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $17.80 | 2025 | |
| Viiv Healthcare Company | $15.95 | 2024 | Apretude |
| Myriad Genetic Laboratories, INC. | $14.14 | 2024 | Myrisk |
| Kowa Pharmaceuticals America, INC. | $13.37 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Rumble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.